Literature DB >> 1900728

Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography.

G V Sawle1, D J Brooks, C D Marsden, R S Frackowiak.   

Abstract

Corticobasal degeneration presents with an asymmetric akinetic-rigid syndrome, apraxia and combinations of supranuclear gaze palsy, myoclonus, and an alien limb. Six patients aged 59-77 yrs, diagnosed on clinical criteria as having corticobasal degeneration, have been studied with positron emission tomography using tracers of dopamine storage capacity and oxygen metabolism. Striatal 18F-6-fluorodopa uptake was reduced in an asymmetric pattern, caudate and putamen being involved in all cases. Uptake into medial frontal cortex was also impaired. Regional cortical oxygen metabolism was most significantly depressed in the superior and posterior temporal, inferior parietal, and occipital associated cortices. Within the frontal lobe, the hypometabolism was chiefly posterior. This unique combination of regional hypometabolism and disruption of the nigrostriatal system is discussed in relation to the clinical features of the disease and is compared with reported findings in other disorders of cognition and movement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900728     DOI: 10.1093/brain/114.1.541

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  26 in total

1.  Progressive frontal gait disturbance with atypical Alzheimer's disease and corticobasal degeneration.

Authors:  M N Rossor; P J Tyrrell; E K Warrington; P D Thompson; C D Marsden; P Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Neuropsychological and neuroimaging correlates in corticobasal degeneration.

Authors:  E Frasson; G Moretto; A Beltramello; N Smania; M Pampanin; C Stegagno; R Tanel; N Rizzuto
Journal:  Ital J Neurol Sci       Date:  1998-10

3.  Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia".

Authors:  A E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

4.  Positron emission tomography studies of neurotransmitter systems.

Authors:  G V Sawle; D J Brooks
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

5.  Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination.

Authors:  G K Wenning; I Litvan; J Jankovic; R Granata; C A Mangone; A McKee; W Poewe; K Jellinger; K Ray Chaudhuri; L D'Olhaberriague; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 6.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Focal cortical hypoperfusion in corticobasal degeneration demonstrated by three-dimensional surface display with 123I-IMP: a possible cause of apraxia.

Authors:  B Okuda; H Tachibana; M Takeda; K Kawabata; M Sugita; M Fukuchi
Journal:  Neuroradiology       Date:  1995-11       Impact factor: 2.804

8.  The nature of apraxia in corticobasal degeneration.

Authors:  R Leiguarda; A J Lees; M Merello; S Starkstein; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

9.  A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.

Authors:  Shinsuke Fujioka; Bradley F Boeve; Joseph E Parisi; Pawel Tacik; Naoya Aoki; Audrey J Strongosky; Matt Baker; Monica Sanchez-Contreras; Owen A Ross; Rosa Rademakers; Vesna Sossi; Dennis W Dickson; A Jon Stoessl; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-08-19       Impact factor: 4.891

10.  Ubiquitin-positive achromatic neurons in corticobasal degeneration.

Authors:  G M Halliday; L Davies; D A McRitchie; H Cartwright; R Pamphlett; J G Morris
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.